ATE255229T1 - Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten - Google Patents

Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten

Info

Publication number
ATE255229T1
ATE255229T1 AT01908032T AT01908032T ATE255229T1 AT E255229 T1 ATE255229 T1 AT E255229T1 AT 01908032 T AT01908032 T AT 01908032T AT 01908032 T AT01908032 T AT 01908032T AT E255229 T1 ATE255229 T1 AT E255229T1
Authority
AT
Austria
Prior art keywords
dpis
bad
dpi
detectable
serum
Prior art date
Application number
AT01908032T
Other languages
English (en)
Inventor
Herath Mudiyanselage At Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Original Assignee
Oxford Glycosciences Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004415A external-priority patent/GB0004415D0/en
Priority claimed from GB0004412A external-priority patent/GB0004412D0/en
Priority claimed from GB0006285A external-priority patent/GB0006285D0/en
Priority claimed from GB0028734A external-priority patent/GB0028734D0/en
Priority claimed from GB0030050A external-priority patent/GB0030050D0/en
Application filed by Oxford Glycosciences Uk Ltd filed Critical Oxford Glycosciences Uk Ltd
Application granted granted Critical
Publication of ATE255229T1 publication Critical patent/ATE255229T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
AT01908032T 2000-02-24 2001-02-26 Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten ATE255229T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0004415A GB0004415D0 (en) 2000-02-24 2000-02-24 Proteins and their use for diagnosis and treatment of schizophrenia
GB0004412A GB0004412D0 (en) 2000-02-24 2000-02-24 Proteins and their use for diagnosis and treatment of bipolar affective disorder and unipolar depression
GB0006285A GB0006285D0 (en) 2000-03-15 2000-03-15 Proteins and their use for diagnosis and treatment of vascular dementia
GB0028734A GB0028734D0 (en) 2000-11-24 2000-11-24 Markers for vascular dementia
US72439100A 2000-11-28 2000-11-28
GB0030050A GB0030050D0 (en) 2000-12-08 2000-12-08 Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (BAD) and unipolar depression
US25483000P 2000-12-12 2000-12-12
US75039500A 2000-12-28 2000-12-28
PCT/IB2001/000259 WO2001063295A2 (en) 2000-02-24 2001-02-26 Dpi-6, a therapeutic biomarker in neurological disorders

Publications (1)

Publication Number Publication Date
ATE255229T1 true ATE255229T1 (de) 2003-12-15

Family

ID=27571144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01908032T ATE255229T1 (de) 2000-02-24 2001-02-26 Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten

Country Status (6)

Country Link
EP (1) EP1224471B1 (de)
JP (1) JP2003528300A (de)
AT (1) ATE255229T1 (de)
AU (1) AU3589101A (de)
DE (1) DE60101305D1 (de)
WO (1) WO2001063295A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029485A2 (en) * 2001-10-02 2003-04-10 Azign Bioscience A/S Specific differential display arrays
WO2006010534A1 (en) * 2004-07-28 2006-02-02 F.Hoffmann-La Roche Ag Dickkopf homolog 3 as target/marker of beta cell failure
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
JP2009092550A (ja) * 2007-10-10 2009-04-30 Japan Health Science Foundation うつ病またはうつ状態の同定方法
JP2013501919A (ja) 2009-08-07 2013-01-17 アフィニマーク テクノロジーズ，インコーポレイテッド 脳脊髄液の免疫的識別のための装置および方法
JP2019512216A (ja) * 2016-02-22 2019-05-16 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル カルシウムチャネルのペプチド阻害剤
CN109549654B (zh) * 2017-09-26 2021-05-04 上海添音生物科技有限公司 一种常见精神疾病辅助筛选试剂盒及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027932A2 (en) * 1996-12-20 1998-07-02 Human Genome Sciences, Inc. Cerebellum and embryo specific protein
DE69842225D1 (de) * 1997-04-16 2011-05-26 Millennium Pharm Inc Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
NZ503343A (en) * 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
CA2366062C (en) * 1999-03-05 2014-06-17 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor

Also Published As

Publication number Publication date
AU3589101A (en) 2001-09-03
EP1224471A2 (de) 2002-07-24
JP2003528300A (ja) 2003-09-24
DE60101305D1 (de) 2004-01-08
WO2001063295A3 (en) 2002-05-23
WO2001063295A2 (en) 2001-08-30
EP1224471B1 (de) 2003-11-26

Similar Documents

Publication Publication Date Title
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
Dyer et al. Mutant protein in Huntington disease is resistant to proteolysis in affected brain
Cavalcante et al. A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia
Perez et al. Hippocampal endosomal, lysosomal, and autophagic dysregulation in mild cognitive impairment: correlation with Aβ and tau pathology
Schroeder et al. Targeting Thioredoxin-1 by dimethyl fumarate induces ripoptosome-mediated cell death
US8263072B2 (en) ADAMTS4 as a blood biomarker and therapeutic target for chronic renal failure
DE69737788D1 (de) Reagenzien und methoden zum nachweis von erkrankungen der brust
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
EP1141728A4 (de) Nachweis von erkrankungen der nieren und behandlung
WO2001013117A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
AU5169998A (en) Methods for detecting cell apoptosis
Végran et al. A short caspase-3 isoform inhibits chemotherapy-induced apoptosis by blocking apoptosome assembly
DE60101305D1 (de) Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
AU3392901A (en) Proteins
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2002090974A3 (de) Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia
JP2024038346A (ja) 血液から癌を診断する方法
WO2001063294A3 (en) Diagnosis of bipolar affective disorder (bad) and unipolar depression
WO2001069261A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
CN106018827B (zh) 一种阿尔茨海默症检测标志物及其检测方法

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties